Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Investor Presentation (July 2026)
31 slides from Radiopharm Theranostics's investor presentation, Jul 24, 2026
Slide 1: A Multi-Asset Radiopharmaceutical Platform
For personal use only ASX: RAD | NASDAQ: RADX A Multi-Asset Radiopharmaceutical Platform Clinical-stage oncology radiopharmaceuticals — diagnostics and therapeutics Capital Raising Presentation July 2026 1
Slide 2: Notice & Disclaimer
Notice & Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS A multi-asset radiopharmaceutical platform — a Phase III-ready imaging lead plus four clinical-stage therapeutics. For personal use only RAD101 HIGHLIGHTS: POSITIVE PHASE 2b READOUT: ≥ 93% of the patients achieved the Primary Endpoint Clear path to Phase III RAD101 large unmet
Slide 4: Company Pipeline in Clinical Stage
Company Pipeline in Clinical Stage First two programs reporting strong clinical data. Additional upside from the other three Phase I trials PROGRAM INDICATION ISOTOPE PHASE I PHASE II PHASE III CATALYSTS For personal use only 18F Positive Phase 2b read-out RAD101 Imaging — brain mets July 2026 Clini
Slide 5: Key Catalysts & Milestones
KEY CATALYSTS & MILESTONES Consistent clinical & regulatory delivery since mid-2025, with multiple value-driving catalysts approaching from mid-2026 into 2027 For personal use only Pharma Partnership Window Achieved Milestones Upcoming Milestones Siemens FDA Phase III RAD101 Partnering / RAD101 Phas
Slide 6: Imaging lead asset — RAD101
RAD 101 DIAGNOSTIC Imaging lead asset — RAD 101 First-in-class PET imaging agent for brain metastases THE AGENT For personal use only Fatty acid synthase (FASN) — a validated target Targets the FASN fatty-acid metabolism pathway FASN Pivalate ¹⁸F Tumor target Targeting molecule PET isotope Detects r
Slide 7: First-in-class PET tracer to advance to Phase 3
RAD 101 DIAGNOSTIC Imaging lead asset — RAD101 First-in-class PET tracer to advance to Phase 3 — near-term value and optionality For personal use only THE NEED THE MARKET High unmet Need - SoC MRI falls short 300,000 Early identification of recurrent brain metastases is urgent need in ~300,000 new b
Slide 8: RAD101 Phase IIb — primary endpoint readout
RAD 101 DIAGNOSTIC RAD101 Phase IIb — primary endpoint readout Primary endpoint met — high concordance with MRI. For personal use only PRIMARY ENDPOINT Concordance with MRI ≥ 93% 28* / 30 patients concordant SUCCESSFULLY ACHIEVED *3/30 Patient data not yet available SECON DARY EN DPOI N T · I N TERI
Slide 9: RAD101 - Next steps to Phase 3
RAD 101 DIAGNOSTIC RAD101 - Next steps to Phase 3 A clear, de-risked path to a Phase 3 start in Q4 2026 For personal use only May 2026 Sep 2026 Q4 2026 MILESTONES Advisory Board FDA protocol meeting Phase 3 start Supportive of Phase 3 Align on trial design Ready to initiate Trial design Supply & log
Slide 10: Partnering opportunity assessment
RAD 101 DIAGNOSTIC Partnering opportunity assessment Radiopharmaceuticals are an actively consolidating sector - over US$10bn of M&A and partnerships in recent years - as Radiopharm advances a de-risked, multi-asset pipeline toward partnering. For personal use only Potential Partners Recent Radiopha
Slide 11: Potential first-in-class diagnostic with commercial scale
RAD 101 DIAGNOSTIC POTENTIAL FIRST-IN-CLASS DIAGNOSTIC WITH COMMERCIAL SCALE ~300,000 patients/year (US), Potential >$500M annual sales (US) For personal use only Potential first-in-class diagnostic with scalable adoption Clear pathway to monetization through partnering or commercialization Comparab
Slide 12: Why RAD101 will be adopted
RAD 101 DIAGNOSTIC Why RAD101 will be adopted Four reasons RAD101 fits — and wins — in post-treatment neuro-oncology imaging. THE NEED THE FIT For personal use only Clear unmet need Fits existing workflow MRI is frequently equivocal in post-treatment brain metastases. PET is already standard — no ne
Slide 13: RAD204 — First-in-class PD-L1 targeted radiotherapy
RAD 204 THERAPEUTIC RAD204 — First-in-class PD-L1 targeted radiotherapy Validated immuno-oncology target For personal use only First-in-class PD-L1 targeted 177Lu radiotherapy POTENTIAL POSITIONING LEAD INDICATION EXPANSION Post-IO NSCLC Multiple solid tumors High unmet-need setting after immunother
Slide 14: RAD204: early efficacy signal
RAD 204 THERAPEUTIC RAD204: early efficacy signal First patient dosed at Cohort 3 (90 mCi) — dose escalation ongoing under a Bayesian (BOIN) design For personal use only TRIAL DESIGN Phase I — Treatment (dose escalation) PRIMARY OBJECTIVES • Safety & tolerability of ¹⁷⁷Lu-RAD204 120 mCi (tbd) • Reco
Slide 15: RAD204: early clinical activity
RAD 204 THERAPEUTIC RAD204: early clinical activity First patient at 90 mCi achieved a confirmed RECIST Partial Response with durable (7+ months) tumor shrinkage For personal use only Partial Response 7+ months PFS Stable disease 2+ months PFS RECIST Confirmed (Pt #7) No evidence of progression Posi
Slide 16: Patient #7 — first patient treated at 90 mCi
RAD 204 THERAPEUTIC Patient #7 — first patient treated at 90 mCi Durable confirmed RECIST partial response across multiple cycles CORONAL CT · RLL PRIMARY NSCLC — progressed after multiple prior therapies For personal use only • External-beam radiotherapy Baseline Expected PFS October ‘25 • Chemothe
Slide 17: RAD204 Investment Case
RAD 204 THERAPEUTIC RAD204 Investment Case Targeted radiotherapy introduces a new For personal use only PD-L1 is the largest and most validated principle combining two synergistic immuno-oncology target mechanisms of action Addressable market (US, post-IO NSCLC) Platform enables continued optimizati
Slide 18: Phase I dose escalation with a favorable safety profile
RAD 202 THERAPEUTIC Phase I dose escalation with a favorable safety profile First two cohorts completed with no DLTs — Dose Level 3 dosed at 130 mCi For personal use only TRIAL DESIGN Phase I — Treatment (dose escalation) PRIMARY OBJECTIVES (PHASE 1) • Safety & tolerability of ¹⁷⁷Lu-RAD202 200 mCi (
Slide 19: RAD202: Cohort #3 expected to complete by September
RAD 202 THERAPEUTIC RAD202: Cohort #3 expected to complete by September Evidence of tumor radiation at Dose Level 3 (130 mCi) For personal use only Completing by September No DLT to date Next dose: 200 mCi 3 patients dosed in Cohort #3 Safety assessment ongoing Escalation planned DOSE LEVEL 3 · 130
Slide 20: Summary
SUMMARY A multi-asset radiopharmaceutical platform — a Phase III-ready imaging lead plus four clinical-stage therapeutics. For personal use only 2026 CATALYSTS 2027 CATALYSTS RAD 101 RAD 204 PIPELINE UPSIDE Successful Phase 2b trial in Brain Strong signal of Clinical Efficacy RAD 202 has very promis
Slide 21: Board & Management
BOARD & MANAGEMENT Leadership with hands-on, successful development and commercial track record LEADERSHIP TEAM SCIENTIFIC ADVISORY BOARD For personal use only Riccardo Canevari Paul Hopper Dr. Dimitris Voliotis Dr. Ken Herrmann Dr. Oliver Sartor Chief Executive Officer Executive Chairman Chief Medi
Slide 22: Capital Raising
For personal use only CAPITAL RAISING Offer details · Use of funds · Indicative timetable 22
Slide 23: Capital Raising Overview
CAPITAL RAISING OVERVIEW The Company is raising ~A$18.5 million1 via a Placement, US Direct Registration Offering & SPP • A two-tranche Placement of fully paid ordinary shares (“New Shares”) to sophisticated and professional investors of ~A$6.7m (before costs)(“Placement”) comprising of: For persona
Slide 24: Use of Funds
USE OF FUNDS Capital raising proceeds will fund its commencement of the RAD101 registrational study while progressing multiple therapeutic programs through key clinical milestones and supporting ongoing strategic partnering initiatives For personal use only SOURCE OF FUNDS A$M CAPITAL RAISE USE OF F
Slide 25: Indicative Timetable
INDICATIVE TIMETABLE Key dates for the proposed offer - indicative only and subject to change Indicative capital raising timetable1 Date (Sydney Time)2 For personal use only Trading Halt Wednesday, 22 July 2026 Placement Bookbuild Opens Wednesday, 22 July 2026 Record Date for SPP (7:00pm AEST) 7:00p
Slide 26: Key Risks
KEY RISKS Pipeline product in Radiopharm’s ability to achieve profitability is dependent on a number of factors, including its ability to complete successful clinical development and not For personal use only trials, obtain regulatory approval for its products and successfully commercialise those pr
Slide 27: Key Risks (cont.)
KEY RISKS (CONT.) Radiopharm may pursue collaborative arrangements with pharmaceutical and life science companies, academic institutions or other partners to complete the development and commercialisation of its products. There is no assurance that Radiopharm will attract and For personal use only A
Slide 28: International Offer Jurisdictions
INTERNATIONAL OFFER JURISDICTIONS This document does not constitute an offer of new ordinary shares (“New Shares”) and free-attaching options (“Options”) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New S
Slide 29: International Offer Jurisdictions (cont.)
INTERNATIONAL OFFER JURISDICTIONS (CONT.) Singapore This document and any other materials relating to the New Shares and Options have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other docume
Slide 30: International Offer Jurisdictions (cont.)
INTERNATIONAL OFFER JURISDICTIONS (CONT.) United States This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares, the Options and the ordinary shares underlying the Options have not been, and will not be, registered und
Slide 31: Thank You
For personal use only Thank You www.radiopharmtheranostics.com 31 31
Radiopharm Theranostics — Investor Presentation (July 2026) on 6ix